Aureos Capital, an emerging markets private equity firm, has launched a programme to manage health risks in its east African investee companies.

The programme, which will cover HIV/Aids, malaria and tuberculosis, has $1m (£504,000, €648,000) funding from the Norwegian government, an Aureos shareholder. It is based on research carried out across east Africa on behalf of Aureos in response to a realisation that HIV/Aids in particular has a significant impact on earnings for local companies.